14 March 2017 - Ipsen Biopharmaceuticals Canada today announced that Health Canada has approved Dysport Therapeutic (abobotulinumtoxinA) for the treatment of patients with cervical dystonia (CD) and adult upper limb spasticity (ULS).

"ULS and CD have a profound impact on the ability of thousands of Canadians to perform daily life tasks," said Dr. Alfonso Fasano, a neurologist at Toronto Western Hospital, Clinician Investigator at Krembil Research Institute and Associate Professor at the Faculty of Medicine of University of Toronto.

Read Ipsen press release